Baicalein ameliorates Alzheimer's disease via orchestration of CX3CR1/NF-κB pathway in a triple transgenic mouse model
Xin-Mei Xie,Jiao-Jiao Hao,Jun-Zhuo Shi,Yun-Feng Zhou,Peng-Fei Liu,Feng Wang,Xiao-Ming Zheng,Xiu-Ying Yu,Chen-Chen Wang,Yi Yan,Guan-Hua Du,Jun-Ke Song,Yang-Yang He,Yang-Yang He,Xiao-Bin Pang,Xiao-Bin Pang,Xiao-Bin Pang
DOI: https://doi.org/10.1016/j.intimp.2023.109994
IF: 5.714
2023-05-01
International Immunopharmacology
Abstract:Alzheimer’s disease (AD) is a common chronic neurodegenerative disease. Some studies have suggested that dysregulation of microglia activation and the resulting neuroinflammation play an important role in the development of AD pathology. Activated microglia have both M1 and M2 phenotypes and inhibition of M1 phenotype while stimulating M2 phenotype has been considered as a potential treatment for neuroinflammation-related diseases. Baicalein is a class of flavonoids with anti-inflammatory, antioxidant and other biological activities, but its role in AD and the regulation of microglia are limited. The purpose of this study was to investigate the effect of baicalein on the activation of microglia in AD model mice and the related molecular mechanism. Our results showed that baicalein significantly improved the learning and memory ability and AD-related pathology of 3 × Tg-AD mice, inhibited the level of pro-inflammatory factors TNF-α, IL-1β and IL-6, promoted the production of anti-inflammatory factors IL-4 and IL-10, and regulated the microglia phenotype through CX3CR1/NF-κB signaling pathway. In conclusion, baicalein can regulate the phenotypic transformation of activated microglia and reduce neuroinflammation through CX3CR1/NF-κB pathway, thereby improving the learning and memory ability of 3 × Tg-AD mice.
pharmacology & pharmacy,immunology